• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: C.R. BARD, INC. (GFO) LUTONIX 035 DRUG COATED BALLOON PTA CATHETER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

C.R. BARD, INC. (GFO) LUTONIX 035 DRUG COATED BALLOON PTA CATHETER Back to Search Results
Model Number 9004
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Death (1802); Reocclusion (1985); Sepsis (2067)
Event Date 05/24/2018
Event Type  Death  
Manufacturer Narrative
Analysis: the device was not returned for evaluation; therefore, the investigation was conducted based on manufacturing records, information obtained from the principal investigator, and the user facility where the index procedure occurred.A lot history review revealed this is the only complaint associated with this lot.A review of the device history record (dhr) indicates the lot was manufactured to specification and sterility records revealed the device was sterile prior to being released for distribution.The patient was discharged from (b)(6) hospital, 17 (seventeen) days after the index procedure.Six (6) days later, the patient was admitted to another medical facility and was diagnosed with sepsis.The patient was treated and fully recovered from the sepsis.Although requested, the cause for the sepsis was not provided.The investigator deemed the sepsis event not related to the study device or index procedure.While being evaluated at another medical facility, the patient was reportedly diagnosed with deteriorating bilateral atherosclerosis obliterans (aso).It was reported the patient and patient¿s family members declined further medical intervention and/or treatment.On (b)(6) 2018, the patient expired.In the opinion of the healthcare professional (hcp), the patient likely expired due to aso, while being hospitalized at the other medical facility.The investigator assessed the deterioration of aso to be possibly related to the study device.Conclusion: the patient's past medical history includes hypertension, dyslipidemia, diabetes, chronic renal disease, coronary artery disease, and rutherford class v in the left leg.The becton dickinson (b)(4) reviewed this event and felt the worsening of aso was due to natural disease progression and not related to the lutonix device that was used four months prior.A localized treatment with the lutonix drug coated balloon catheter would not worsen the patient¿s aso.The other medical facility was contacted for additional information; however, additional information has not been received at the time of this report.If additional information becomes available, a supplemental report will be provided with the relevant information.
 
Event Description
It was reported through a post market clinical study that during the index procedure, a lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter was used to treat the target lesion located in the left superficial femoral artery (sfa) on (b)(6) 2018.The patient was discharged from the user facility, (b)(6) hospital, on (b)(6) 2018.Allegedly, the patient presented with sepsis on (b)(6) 2018 at another medical facility.The patient was hospitalized at the other medical facility, where the patient reportedly fully recovered from the sepsis during hospitalization.The investigator assessed the sepsis event to be not related to the study device or index procedure.While being evaluated at the other medical facility, the patient was reportedly diagnosed with deteriorating bilateral atherosclerosis obliterans (aso).Furthermore, it was reported the patient and patient¿s family members declined further medical intervention and /or treatment.On (b)(6) 2018, the patient expired.In the opinion of the healthcare professional (hcp), the patient likely expired due to aso, while being hospitalized at the other medical facility.The investigator has assessed that the deterioration of aso was possibly related to the study device, but not related to the index procedure.The other medical facility has been contacted for additional information; however, no additional information is available.The sample was discarded by the user facility and is not available for evaluation.
 
Manufacturer Narrative
The event description had the following sentences changed from "while being evaluated at the other medical facility, the patient was reportedly diagnosed with deteriorating bilateral atherosclerosis obliterans (aso).Furthermore, it was reported the patient and patient¿s family members declined further medical intervention and /or treatment." to "while being evaluated at the other medical facility, the patient reportedly had ulcers and necrosis in both legs.Furthermore, the patient was reportedly diagnosed with deteriorating bilateral atherosclerosis obliterans (aso).However, it was reported the patient and patient¿s family members declined further medical intervention, bypass surgery for left anterior tibial artery, and/or treatment." the other relevant history had the following added "heart failure and aortic valve stenosis" the operator of device - other had the following information added "cardiovascular internal medicine" the report source - other field had the following information added "levant japan." analysis conclusion: the conclusion had the following information added "heart failure and aortic valve stenosis" corrected data: the analysis had the following information changed from "while being evaluated at the other medical facility, the patient was reportedly diagnosed with deteriorating bilateral atherosclerosis obliterans (aso).Furthermore, it was reported the patient and patient¿s family members declined further medical intervention and /or treatment." to "while being evaluated at the other medical facility, the patient reportedly had ulcers and necrosis in both legs.Furthermore, the patient was reportedly diagnosed with deteriorating bilateral atherosclerosis obliterans (aso).However, it was reported the patient and patient¿s family members declined further medical intervention, bypass surgery for left anterior tibial artery, and/or treatment." h3 analysis: the device was not returned for evaluation; therefore, the investigation was conducted based on manufacturing records, information obtained from the principal investigator, and the user facility where the index procedure occurred.A lot history review revealed this is the only complaint associated with this lot.A review of the device history record (dhr) indicates the lot was manufactured to specification and sterility records revealed the device was sterile prior to being released for distribution.The patient was discharged from kokura memorial hospital, 17 (seventeen) days after the index procedure.Six (6) days later, the patient was admitted to another medical facility and was diagnosed with sepsis.The patient was treated and fully recovered from the sepsis.Although requested, the cause for the sepsis was not provided.The investigator deemed the sepsis event not related to the study device or index procedure.While being evaluated at the other medical facility, the patient reportedly had ulcers and necrosis in both legs.Furthermore, the patient was reportedly diagnosed with deteriorating bilateral atherosclerosis obliterans (aso).However, it was reported the patient and patient¿s family members declined further medical intervention, bypass surgery for left anterior tibial artery, and/or treatment.On (b)(6) 2018, the patient expired.In the opinion of the health care professional (hcp), the patient likely expired due to aso, while being hospitalized at the other medical facility.The investigator assessed the deterioration of aso to be possibly related to the study device.Conclusion: the patient's past medical history includes hypertension, dyslipidemia, diabetes, chronic renal disease, coronary artery disease, heart failure, aortic valve stenosis and rutherford class v in the left leg.The becton dickinson interventional segment medical director reviewed this event and felt the worsening of aso was due to natural disease progression and not related to the lutonix device that was used four months prior.A localized treatment with the lutonix drug coated balloon catheter would not worsen the patient¿s aso.The other medical facility was contacted for additional information.If additional information becomes available, a supplemental report will be provided with the relevant information.
 
Event Description
It was reported through a post market clinical study that during the index procedure, a lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter was used to treat the target lesion located in the left superficial femoral artery (sfa) on (b)(6) 2018.The patient was discharged from the user facility, kokura memorial hospital, on (b)(6) 2018.Allegedly, the patient presented with sepsis on (b)(6) 2018 at another medical facility.The patient was hospitalized at the other medical facility, where the patient reportedly fully recovered from the sepsis during hospitalization.The investigator assessed the sepsis event to be not related to the study device or index procedure.While being evaluated at the other medical facility, the patient reportedly had ulcers and necrosis in both legs.Furthermore, the patient was reportedly diagnosed with deteriorating bilateral atherosclerosis obliterans (aso).However, it was reported the patient and patient¿s family members declined further medical intervention, bypass surgery for left anterior tibial artery, and/or treatment.On (b)(6) 2018, the patient expired.In the opinion of the health care professional (hcp), the patient likely expired due to aso, while being hospitalized at the other medical facility.The investigator has assessed that the deterioration of aso was possibly related to the study device, but not related to the index procedure.The other medical facility has been contacted for additional information; however, no additional information is available.The sample was discarded by the user facility and is not available for evaluation.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
LUTONIX 035 DRUG COATED BALLOON PTA CATHETER
Type of Device
DRUG COATED BALLOON PTA CATHETER
Manufacturer (Section D)
C.R. BARD, INC. (GFO)
289 bay road
queensbury NY 12804
MDR Report Key8261135
MDR Text Key133538854
Report Number3006513822-2019-00005
Device Sequence Number1
Product Code ONU
UDI-Device Identifier00801741122873
UDI-Public(01)00801741122873
Combination Product (y/n)N
PMA/PMN Number
P130024
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type distributor,foreign,health pr
Type of Report Initial,Followup
Report Date 03/29/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date09/06/2020
Device Model Number9004
Device Catalogue NumberLX35756605F
Device Lot NumberGFBW0341
Was Device Available for Evaluation? No
Event Location Hospital
Initial Date Manufacturer Received 12/19/2018
Initial Date FDA Received01/18/2019
Supplement Dates Manufacturer Received03/25/2019
Supplement Dates FDA Received03/29/2019
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Death; Hospitalization;
Patient Age74 YR
Patient Weight59
-
-